Isologic Innovative Radiopharmaceuticals

What Isologic Innovative Radiopharmaceuticals does

Isologic Innovative Radiopharmaceuticals Ltd is a privately held Canadian radiopharmaceutical company founded in 2014 and headquartered in Dorval, Quebec. The company produces and distributes PET and SPECT radiopharmaceuticals for cancer diagnosis (including prostate cancer via PSMA imaging and oncology via F-18 FDG), cardiac imaging (Tc-PYP pyrophosphate), neurological disease detection (Alzheimer's disease via NeuraCeq/florbetaben F18), and thyroid cancer therapy (I-131 capsules). Its manufacturing infrastructure includes negative ion cyclotrons with multi-target capability for producing six different isotopes, synthesis modules for over 10 PET imaging agents, hot cells, clean rooms for GMP-compliant sterile production, and Ge-68/Ga-68 generator systems for on-demand radiopharmaceutical preparation.

The company operates a nationwide distribution network spanning seven Canadian locations (Dorval, Toronto, Lachine, Burlington, Ottawa, Quebec City, and Vancouver) serving more than 230 hospitals and independent healthcare facilities. Daily throughput is approximately 2,100 radiopharmaceutical preparations, with 100,000 containers shipped annually enabling roughly 600,000 patient diagnoses per year. Product distribution includes unit-dose syringes for individual patient injections, with real-time isotope geolocation tracking for time-sensitive logistics. Exclusive Canadian distribution partnerships with global radiopharmaceutical innovators (Lantheus, Telix Pharmaceuticals for Illuccix, Piramal Imaging for NeuraCeq, IRE Elit for Galli Eo) form the core of an open formulary of Health Canada-authorized products.

Isologic generates revenue through radiopharmaceutical product sales, on-site SPECT/PET radiopharmacy services, cyclotron target irradiation services, cold kit distribution, and contract development and manufacturing (CDMO) services for international partners seeking Canadian market entry. The customer base spans acute care hospitals, university medical centers, independent diagnostic imaging clinics, cardiology centers, research institutions, and international radiopharmaceutical companies. The company holds a Canadian Nuclear Safety Commission (CNSC) license and operates GMP/BPF-compliant facilities, with regulatory expertise serving as a barrier to entry and a competitive moat.

Name

Isologic Innovative Radiopharmaceuticals

Legal name

Isologic Innovative Radiopharmaceuticals Ltd

Website

https://isologicradiopharm.ca

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

Isologic Innovative Radiopharmaceuticals is a privately held Canadian radiopharmaceutical company that produces and distributes PET and SPECT imaging agents to over 230 hospitals nationwide, with seven manufacturing facilities and an open formulary of Health Canada-authorized products for cancer, cardiac, and neurological disease diagnosis.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA)

akta.pro secondary industries

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH), Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

Keywords

• Radiopharmaceutical manufacturing
• PET imaging agents
• SPECT radiopharmaceuticals
• Medical isotope production
• Nuclear medicine supplies

Headquarters

HQ city

Burlington

HQ country

Canada

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Radiopharmaceutical Product Sales: Sale of PET and SPECT radiopharmaceutical products including Illuccix, I-131, F-18 FDG, Galli Eo, NeuraCeq, NaF Plus, and Pyrophosphate. Products distributed daily to hospitals and healthcare facilities nationwide.
2. Cyclotron Target Irradiation Services: Contract manufacturing services using cyclotron facilities for radioisotope production, part of CDMO service offerings.
3. On-site SPECT/PET Services: On-site radiopharmacy services including dose preparation for SPECT and PET imaging at customer facilities.
4. Cold Kit Distribution: Distribution of cold kits including Pyrophosphate and Antimony Sulfide Colloid Tc99m for lymphoscintigraphy.
5. CDMO Services: Contract development and manufacturing organization services for radiopharmaceutical partners including market entry support for Canadian commercialization.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Isologic manufactures, distributes, and dispenses PET and SPECT radiopharmaceutical products (including Illuccix, NeuraCeq, F-18 FDG, Galli Eo, I-131, NaF Plus, Pyrophosphate, and Antimony Sulfide Colloid Tc99m) for cancer, cardiac, and neurological imaging in Canadian hospitals and independent healthcare facilities. Beyond products, the company operates cyclotron target irradiation, on-site SPECT/PET radiopharmacy, dose preparation, cold kit distribution, logistics and warehousing, and CDMO services for international radiopharmaceutical partners seeking Canadian market entry.

Product overview

Isologic Innovative Radiopharmaceuticals is a nationwide radiopharmaceutical company providing a comprehensive portfolio of PET and SPECT imaging products and nuclear medicine services across Canada. The core product portfolio includes: Illuccix® (PSMA-11 for prostate cancer PET), NeuraCeq® (florbetaben F18 for Alzheimer's PET imaging), F-18 FDG (fluorodeoxyglucose for oncology PET), Galli Eo® (Gallium-68 generator), I-131 capsules (for thyroid cancer), NaF Plus (sodium fluoride for bone imaging), and Pyrophosphate injection kits. The company operates cyclotron facilities to produce F-18 and provides on-site SPECT/PET radiopharmacy services, CDMO capabilities, cold kit distribution, logistics, warehousing, and dose preparation. With strategic partnerships including Lantheus, Telix Pharmaceuticals, and IRE Elit, Isologic enables global radiopharmaceutical innovators to commercialize products in the Canadian market. The company serves over 230 hospitals and independent healthcare facilities, preparing and distributing approximately 2,100 radiopharmaceuticals daily and diagnosing 600,000 patients annually.

Differentiator

Problem solved

Functional benefit

Brands

• Illuccix: PSMA PET imaging agent for prostate cancer detection (Ga-68 Gozetotide Preparation Kit)
• NeuraCeq
• Galli Eo
• NaF Plus
• F-18 FDG
• Pyrophosphate

Products and services

• Illuccix® (Ga-68 Gozetotide Preparation Kit / PSMA-11) Ga-68 Gozetotide Preparation Kit (PSMA-11) for PET imaging of prostate cancer. Available as cold kit or single dose for clinical use in detecting and guiding treatment decisions in advanced prostate cancer.
• NeuraCeq® (florbetaben F18 injection) Florbetaben F18 injection radiopharmaceutical for PET imaging of beta-amyloid neuritic plaque density in the brain. Used for early diagnosis of Alzheimer's disease in patients with cognitive impairment.
• F-18 FDG (fluorodeoxyglucose) [F-18]-fluorodeoxyglucose radiopharmaceutical produced via cyclotron for PET imaging of cancer patients for diagnosis, treatment planning, and clinical trials.
• Galli Eo® (Germanium-68/Gallium-68 generator) Germanium-68/Gallium-68 generator for producing Gallium-68 radiopharmaceuticals on-site. Enables point-of-care radiopharmaceutical preparation for PET imaging.
• I-131 Capsules (Iodine-131) Iodine-131 capsules for diagnosis and treatment of thyroid cancer. Available in therapeutic and diagnostic formulations.
• NaF Plus (F-18 Sodium Fluoride) F-18 Sodium fluoride PET imaging agent for bone scanning applications.
• Pyrophosphate Injection Kit Cold kit for preparation of technetium pyrophosphate (Tc-PYP) for cardiac imaging. Stored at room temperature, eliminating patient travel requirements for Tc-PYP scanning.
• Antimony Sulfide Colloid Tc99m Tc99m radiopharmaceutical injection for lymphoscintigraphy and localization of lymphatic drainage.
• Cyclotron Target Irradiation Services Production of radioisotopes via cyclotron including Fluorine-18 (F-18) for incorporation into PET radiopharmaceuticals.
• On-Site SPECT/PET Radiopharmacy Services On-site radiopharmaceutical preparation and dispensing services for hospitals and healthcare facilities.
• CDMO Services (Contract Development and Manufacturing) Contract development and manufacturing organization services for radiopharmaceutical development and production, including market entry support for Canadian commercialization.
• Radiopharmaceutical Logistics Services Transportation of radiopharmaceuticals in shielded containers meeting international standards, including compliance with Transport Canada regulations. Provides real-time isotop location tracking for customer delivery planning.
• SPECT and PET Dose Preparation Services Preparation of patient-specific SPECT and PET doses for direct injection, following GMP and BPF standards.
• Canadian Market Entry Services Strategic partner services for international radiopharmaceutical companies entering the Canadian market, including regulatory support and commercialization.

Quantifiable outcome

• 2,100 radiopharmaceuticals prepared and distributed daily
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Telix PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 22 June 2022License and distribution agreement for Illuccix (Ga-68 Gozetotide Preparation Kit, PSMA-11) for prostate cancer PET imaging in Canada. Isologic commercializes Telix's investigational prostate cancer imaging agent for the Canadian market.
• Centre for Probe Development and Commercialization (CPDC)minorChannel Partner/ Reseller/ Distributor · 1 December 2020Acquisition of FDG Canadian distribution business from CPDC. All FDG customers previously serviced by CPDC transitioned to Isologic's Toronto (Sunnybrook) facility.
• IRE ElitcoreChannel Partner/ Reseller/ Distributor · 5 December 2019Partnership for Galli Eo, the Germanium/Gallium-68 generator approved as a drug in Canada. IRE Elit received Health Canada Notice of Compliance for Galli Eo, distributed through Isologic's network.
• Lantheus Medical ImagingcoreStrategic or Co-development Partner · 28 February 2017Asset purchase agreement for acquisition of Canadian radiopharmacy and Gludef manufacturing and distribution operations including facilities in Dorval, Quebec; Quebec City, Quebec; Mississauga, Ontario; and Vancouver, British Columbia.
• Sunnybrook Health Sciences CentrecoreStrategic or Co-development Partner · 7 June 2015Partnership with Sunnybrook Health Sciences Centre for establishment of cyclotron and radiopharmaceutical manufacturing facility at Toronto location, expanding access to positron emitting radiopharmaceuticals in Greater Toronto Area.
• Piramal Imaging SAcoreStrategic or Co-development Partner · 4 June 2015Strategic partnership and licensing agreement providing Isologic with exclusive rights to manufacture, market, and distribute Neuraceq (florbetaben F18 injection) for beta-amyloid PET imaging for Alzheimer's disease throughout Canada. Technical transfer of manufacturing and quality control processes completed.
• Canadian Association of Nuclear Medicine (ACMN/CANM)coreStrategic or Co-development PartnerCollaboration between Isologic and CANM is essential for ensuring nuclear medicine physicians across Canada have access to critical isotopes for diagnostic and therapeutic procedures. Partnership impacts patient care and advances nuclear medicine in Canada.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Telix Pharmaceuticals: Developer of Illuccix (Ga-68 PSMA-11), the prostate cancer imaging agent that Isologic distributes in Canada. Telix is both partner and adjacent peer; comparable in radiopharmaceutical commercialization focus, though Telix is the IP owner rather than a distributor.
• BWX Technologies (BWXT Medical): Produces medical radioisotopes including Mo-99/Tc-99m and operates radiopharmaceutical manufacturing for global markets. Comparable in isotope production and supply chain role, particularly relevant given shared dependence on reactor/cyclotron infrastructure.

Broad incumbents

• Bracco Imaging: Global imaging agent company with portfolio spanning X-ray, MRI, and nuclear medicine contrast agents and radiopharmaceuticals. Comparable in radiopharmaceutical manufacturing and distribution at scale, with broader diagnostic imaging footprint.
• PETNET Solutions (Siemens Healthineers): Operates a large network of PET radiopharmacy centers producing F-18 FDG and other PET tracers across the US and select international markets. Direct competitor in cyclotron-based PET radiopharmaceutical production and distribution, with broader Siemens imaging portfolio backing.
• Curium Pharma: One of the world's largest nuclear medicine companies, manufacturing and distributing SPECT, PET, and therapeutic radiopharmaceuticals globally. Comparable in PET/SPECT product breadth and CDMO/service capabilities; larger scale with multi-region presence.
• Cardinal Health Radiopharmaceuticals: Operates one of the largest radiopharmaceutical distribution networks in the US, providing SPECT and PET tracers to hospitals and imaging centers. Directly comparable business model (radiopharmacy distribution to hospitals) with broader healthcare distribution parent.
• GE Healthcare (GE Health): Major diagnostic imaging and radiopharmaceutical company offering PET and SPECT tracers plus the imaging hardware that consumes them. Comparable as a vertically integrated radiopharma player, though at much larger scale across multiple imaging modalities.
• Lantheus Holdings: Leading radiopharmaceutical-focused company with proprietary products (e.g., Pylarify PSMA PET, Definity) plus legacy radiopharmacy operations. Previously owned the Canadian operations Isologic acquired in 2017; serves as both product licensor and broad strategic peer.
• Novartis Radioligand Therapy: Owner of Lutathera and Pluvicto radioligand therapies that require Lu-177 supply chain infrastructure. Strategic relevance to Isologic as the company is investing in 18 MeV cyclotron capacity that could enable future Lu-177 production for therapeutic radiopharmaceuticals.

Regional players

• Canadian Nuclear Laboratories (CNL): Canadian nuclear science organization operating research reactors and isotope production facilities including historically the Chalk River reactor supplying Mo-99. Relevant regional peer in Canadian isotope supply chain, though structured as a government-owned lab rather than commercial radiopharmacy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@Isologic
• Facebookfacebook.com/Isologic-Innovative-Radiopharmaceuticals-105394665319790
• LinkedInlinkedin.com/company/isologic-innovative-radiopharmaceuticals
• Instagraminstagram.com/isologic.radiopharmaceutiques

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Isologic Innovative Radiopharmaceuticals